Abstract Objective To analyze the pattern of failure in relation to pre-treatment [ 18 F] FDG-PET/CT uptake head and neck squamous cell carcinoma (HNSCC) patients treated with definitive radio-chemotherapy (RT-CHT). Methods materials From 2012 2016, 87 HNSCC RT-CHT, intensity modulated radiation therapy simultaneous integrated boost, underwent (PET pre ), MRI/CT for radiotherapy (RT) planning p...

BACKGROUND The standardized uptake value (SUV) is the most common estimate of metabolic activity used in clinical positron emission tomography (PET). Several biological and technological factors influence the accurate SUV calculation. PURPOSE To assess another potential source of variability of the SUV, the variations in urinary excretion of fluorodeoxyglucose (FDG). MATERIAL AND METHODS Tw...

Purpose To investigate effects of radiotherapy (RT) and erlotinib on pulmonary glucose uptake using 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) positron emission tomography (PET) during and after treatment of non-small cell lung cancer (NSCLC) and to identify associations between serum cytokine levels and lung glucose uptake. Material and methods Twenty-seven patients with advanced NSCLC, recei...

RATIONALE to evaluate the role of 18F-fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) integrated with computer tomography (CT) scan [(18)F]FDG-PET/CT in the staging and target volume definition in Intensity Modulated RapidarcTM Delivery (RA-IMRT) in cervical cancer. METHODS From June 2010 to December 2011, 66 patients affected by cervical cancer, candidates for definitive or ...

INTRODUCTION Glycolytic activity and hypoxia are associated with poor prognosis and radiation resistance. Including both the tumor uptake of 2-deoxy-2-[18 F]-fluorodeoxyglucose (FDG) and the proposed hypoxia tracer copper(II)diacetyl-bis(N4)-methylsemithio-carbazone (Cu-ATSM) in targeted therapy planning may therefore lead to improved tumor control. In this study we analyzed the overlap between...

PURPOSE Validation of dose escalation through FDG-PET dose painting (DP) for oropharyngeal squamous cell carcinoma (SCC) requires randomized clinical trials with large sample size, potentially involving different treatment planning and delivery systems. As a first step of a joint clinical study of DP, a planning comparison was performed between Tomotherapy HiArt® (HT) and Varian RapidArc® (RA)....

BACKGROUND AND PURPOSE The aim of this study is to derive "dose painting by numbers" prescriptions from retrospectively observed recurrence volumes in a patient group treated with conventional radiotherapy for head and neck squamous cell carcinoma. MATERIALS AND METHODS The spatial relation between retrospectively observed recurrence volumes and pre-treatment standardized uptake values (SUV) ...

PURPOSE Dabrafenib is a selective, potent ATP-competitive inhibitor of the BRAFV600-mutant kinase that has demonstrated efficacy in clinical trials. We report the rationale for dose selection in the first-in-human study of dabrafenib, including pharmacokinetics, tissue pharmacodynamics, 2[18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) pharmacodynamics, and dose-response rel...

OBJECTIVES Clinical tumor imaging with (18)F-FDG in PET is growing in demand. This article will provide a review of current patient preparation and imaging techniques. The goal is to make the PET study as noninvasive as possible for the patient while obtaining quality images. Communication and coordination when scheduling these studies involves the patient and radiopharmacy, scanner, and suppor...

BACKGROUND Positron emission tomography (PET) with [2-18 F]-2-fluoro-2-deoxy-D-glucose ([18 F]FDG-PET) was acquired at multiple time-points a) to monitor the early response to RO5126766 (CH5126766) in xenograft models b) to evaluate non-invasive small animal [18 F]FDG-PET imaging as a biomarker for MEK inhibitors for translation into dose-finding studies in cancer patients and c) to explore the...